Clinical trial
Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome
NCT00030550 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00030550 |
|---|---|
| Title | Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome |
| Official title | A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial Assessing The Safety And Efficacy Of Thalidomide (THALOMID) For The Treatment Of Anemia In Red Blood Cell Transfusion-Dependent Patients With Myelodysplastic Syndromes |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Drug |
| Interventions | thalidomide |
| Start date | Sep 1, 2001 |
| Primary completion | Jun 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: